Abstract
Long-term quality of life (QoL) for stage II/III rectal cancer survivors in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS)
Journal of clinical oncology, Vol.32(3_suppl), pp.584-584
01/20/2014
DOI: 10.1200/jco.2014.32.3_suppl.584
Abstract
584 Background: Standard therapy for stage II/III rectal cancer includes surgery, radiation, and chemotherapy. Multiple trials demonstrated neoadjuvant chemoradiation (CRT) provides better local control and decreased morbidity compared to adjuvant CRT, though differences in overall survival and long-term QoL have not been demonstrated. We examined impact of treatment (pre-op CRT/post-op CRT/no CRT) on long-term QoL. Methods: CanCORS patients with survey/medical record data diagnosed in 2003-2005 with stage II/III rectal (non-rectosigmoid) cancer had resection and survived > 7 years were included. QoL (SF-36, EQ-5D) measures and defecation problems were derived from surveys at 14 months and 7 years post-diagnosis. Mean scores were adjusted for the following when significant: age, gender, stage, sphincter preservation, comorbidities, and baseline self-reported health status and QoL scores. Results: Of 119 patients, 53% received pre-op CRT, 23% post-op CRT, and 24% no CRT. Of 114 patients with 14-month follow-up, Pre-op CRT and No CRT groups had better EQ-5D adjusted mean scores but worse defecation scale (DS) scores compared to the Post-op CRT group. Of 49 disease-free survivors with 7 years follow-up, there were no differences among groups in QoL scores, but the No CRT group had better DS scores than other groups. Conclusions: No major differences were detected in long-term QoL based on treatment aside from the DS, though sample sizes became small. Regardless of treatment, long term (7y) mental health and vitality were generally comparable to U.S. norms, while physical health and overall health status (EQ-5D) were somewhat lower. [Table: see text]
Details
- Title: Subtitle
- Long-term quality of life (QoL) for stage II/III rectal cancer survivors in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS)
- Creators
- Mary E Charlton - University of Iowa College of Public Health/VA Center for Comprehensive Access and Delivery, Research and Evaluation, Iowa City, IAKaryn Beth Stitzenberg - Division of Surgical Oncology and Endocrine Surgery, University of North Carolina School of Medicine, Chapel Hill, NCChi Lin - University of Nebraska Medical Center, Omaha, NEGrelda Yazmin Juarez - Department of Biostatistics, University of Iowa, Iowa city, IAThorvardur Ragnar Halfdanarson - Mayo Clinic, Phoenix, AZJane F Pendergast - University of Iowa College of Public Health, Iowa City, IAElizabeth A Chrischilles - University of Iowa College of Public Health, Iowa City, IARobert B Wallace - University of Iowa College of Public Health, Iowa City, IA
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.32(3_suppl), pp.584-584
- DOI
- 10.1200/jco.2014.32.3_suppl.584
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 01/20/2014
- Academic Unit
- Pharmacy; Epidemiology; Biostatistics; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984214681402771
Metrics
12 Record Views